1. Terns Pharmaceuticals reports 74% MMR in CML trial of TERN-701. 2. Safety profile underscores tolerability; no dose-limiting toxicities observed. 3. Analysts predict TERN-701 may disrupt market share of Novartis’ Scemblix. 4. TERNS shares drop 4.25%, indicative of market skepticism post-data release.
FAQ
Why Bearish?
Terns' positive trial data suggests competitive threat to NVS, impacting investors' sentiment.
How important is it?
Disruptive potential of TERN-701 against NVS' Scemblix could significantly affect NVS's market share.
Why Short Term?
Immediate concern as market reacts to potential therapy competition, evidenced by TERN's share drop.